Studies show increased risk of blood clots when taking oral contraception with drospirenone

( -- Two new drug safety studies conducted by researchers at Boston University School of Medicine (BUSM) provide strong evidence that women taking oral contraception with drospirenone have an increased risk of nonfatal venous thromboembolism, or blood clots, compared to women taking oral contraception with levonorgestrel.

The two studies were led by Susan S. Jick, D.Sc., director of the Boston Collaborative Drug Surveillance Program at BUSM and professor of Epidemiology at Boston University School of Public Health. The results are published in the .

A number of studies examining the risk of nonfatal in women taking containing drospirenone have recently been published, but, according to Jick, have had limitations. The previous studies did not take into account women who had additional risk factors for blood clots, including a recent surgery, pregnancy or lower limb injury. Additionally, some of the other studies did not take into account previous instances of blood clots.

"When doing research to understand drug safety, certain methods need to be used, and our study addressed the limitations of the others," said Jick.

Jick and her colleagues conducted the two studies simultaneously using two different data resources - one from the United Kingdom and the other from the United States. In both studies, participants were women between the ages of 15 and 44 who had received drospirenone-containing or levonorgestrel-containing oral contraception and had not experienced a blood clot before, nor did they have additional risk factors.

The UK study found that women taking drospirenone contraception had a three-fold higher risk of non-fatal blood clots compared with women taking levonorgestrel contraception. In the study examining women in the US, women taking drospirenone contraception had double the risk of non-fatal blood clots compared with women taking levonorgestrel contraception.

"Our data clearly shows an increased risk in women taking drospirenone contraceptives compared to contraceptives," said Jick. "It is important for women to be informed about the risks and benefits of the different oral contraceptives so they can make informed decisions."

Provided by Boston University School of Medicine

not rated yet
add to favorites email to friend print save as pdf

Related Stories

New warning OK'd for birth control patch

Jan 21, 2008

The U.S. Food and Drug Administration has approved a warning for the Ortho Evra Contraceptive Transdermal Patch label concerning the risk of blood clots.

FDA panel to consider new 'morning-after pill'

Jun 08, 2010

A Food and Drug Administration advisory committee will meet June 17 to consider whether the agency should approve a new emergency contraceptive that studies show is more effective than Plan B, the only "morning-after pill" ...

'Morning After Pill' Works up to 5 Days After Sex

Feb 22, 2010

( -- A team of researchers from the United States and Europe has published new evidence supporting the use of ulipristal acetate as an effective alternative to levonorgestrel (marketed as Plan B®) for emergency ...

Recommended for you

Expression of privilege in vaccine refusal

15 hours ago

Not all students returning to school this month will be up to date on their vaccinations. A new study conducted by Jennifer Reich, a researcher at the University of Colorado Denver, shows that the reasons why children may ...

Using computers to design drugs

Aug 22, 2014

Designing a new medicine is an expensive and time consuming business. Typically it takes around $2 billion and ten years for a new drug to move from its initial design in the lab, to the clinic. All the ...

Lilly psoriasis drug fares well in late-stage test

Aug 22, 2014

Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease.

User comments